Karyopharm Therapeutics
KPTI
154 hedge funds and large institutions have $334M invested in Karyopharm Therapeutics in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 63 increasing their positions, 39 reducing their positions, and 24 closing their positions.
63% more call options, than puts
Call options by funds: $1.83M | Put options by funds: $1.12M
62% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 39
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
5% more funds holding
Funds holding: 147 → 154 (+7)
0.22% more ownership
Funds ownership: 5.57% → 5.79% (+0.22%)
8% less capital invested
Capital invested by funds: $364M → $334M (-$29.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$44.5M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$19.9M |
| 3 |
AC
Armistice Capital
New York
|
+$17.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$9.48M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$4.96M |
| 2 |
ACM
Altium Capital Management
New York
|
-$4.09M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$3.44M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.34M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$2.92M |
KPTI Hedge Fund Activity: Q4 2022 in Review
154 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2022, worth a combined $334M — down 8.2% from $364M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new KPTI positions and 24 closed out — a net gain of 8 holders — while 63 added to existing stakes and 39 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $44.5M. The largest seller was Rice Hall James & Associates, exiting entirely with an estimated $4.96M sold.
- 154 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2022, up from 147 in Q3 2022.
- Funds reported $334M of Karyopharm Therapeutics stock for Q4 2022, down 8.2% quarter-over-quarter.
- 32 funds opened new Karyopharm Therapeutics positions in Q4 2022 and 24 closed out, a net change of +8 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2022 was Avidity Partners Management, an estimated $44.5M added.
- The largest Karyopharm Therapeutics seller in Q4 2022 was Rice Hall James & Associates, an estimated $4.96M sold.
Based on aggregated 13F filings for Q4 2022.